Introduction
Gene therapeutic intervention for HIV-1 infection requires not only optimization of delivery protocols, but also depends on the identification of effective antiviral genes. Due to concerns about immune-mediated rejection of cells engineered to express protein products, 1 RNAbased antivirals have been extensively explored as antagonists of HIV-1 replication. Three basic types of RNA antivirals have been described: antisense, ribozyme and decoy molecules. 2 Antisense and ribozyme strategies require sequence conservation of their RNA targets for continued activity, and may therefore be susceptible to viral escape resulting from the high mutation rate of HIV-1. By contrast, an RNA decoy is designed to interact specifically with a protein target; to escape, the virus must alter not only protein coding sequences but also the natural viral RNA ligand. In this way, RNA decoys may represent a more versatile and long-lived antiviral strategy.
The two most common targets of decoy strategies are Tat and Rev, the accessory proteins responsible for transactivation of expression and nucleocytoplasmic export of unspliced RNA, respectively. 3, 4 In such strategies, RNA decoys are designed to mimic the transactivation responsive (TAR) and Rev responsive (RRE) elements, respectively. However, this approach may cause unintended cellular toxicity. TAR has been shown to inhibit transcription globally in a cell extract transcription system, 5 and at high input amounts of virus and significantly delayed viral replication for up to 4 weeks. An investigation of the mechanism of inhibition revealed that in these cell lines the packaging efficiency of the genomic HIV-1 transcript was unaffected. Further studies identified an antiviral effect on both HIV-1 and HIV-2 that did not correlate with decoy expression, and was substantially independent of CD4 expression or cellular proliferative capacity. Study of these resistant cell lines may lead to new insights into mechanisms of inhibition of HIV-1 replication. Gene Therapy (2001) 8, 157-165.
in vitro-selected Rev aptamers, designed to minimize the amount of viral sequence included, have shown reduced efficacy compared with the full-length RRE sequence. 6 In addition, the reported synergistic activity of multiple RNA-based antivirals 6 suggests that uncovering novel targets for decoy intervention will allow design of powerful multi-component inhibitory cassettes. In particular, the suggestion that late stages of HIV-1 replication might be refractory to drug intervention in a model of lentiviral latency 7 emphasizes the potential importance of identifying post-transcription targets. For these reasons, we explored a strategy designed to interfere with the late assembly process of RNA encapsidation.
Packaging of the dimeric RNA into HIV-1 virions requires the trans-acting Gag structural protein and cisacting packaging signals contained at the 5Ј end of the genomic transcript. 8 Although motifs present in the transcribed portions of the 5Ј LTR can contribute to encapsidation, the most important packaging determinants are found in the 5Ј untranslated leader. This core packaging signal element (⌿) is predicted to fold into a stable clover-leaf secondary structure. 9 We hypothesized that expression of this structured RNA region in an HIVinfected cell would compete with viral genomic RNA for Gag binding, resulting in the production of particles deficient in viral RNA.
There is some evidence to suggest such packaging interference may be possible. While initial investigations of the decoy effects of HIV-1 leader transcripts yielded mixed results, [10] [11] [12] [13] [14] [15] [16] more recent reports have suggested that competition with HIV-1 packaging is feasible. [17] [18] [19] These more recent studies used HIV-1 vectors or vector sequences, however, meaning that Tat and Rev decoy effects could not be excluded. By contrast, we were interested in studying minimal, non-mobilizable ⌿ sequences for packaging interference.
We report that Jurkat T cells expressing the core packaging signal sequence can be profoundly resistant to HIV-1 replication. Surprisingly, this inhibition is independent of any direct interference with RNA encapsidation and may reveal cellular mechanisms of viral inhibition that have the potential to confound similar analyses of RNA-based antiviral strategies. Investigation of these mechanisms may lead to identification of novel antiviral modalities to inhibit HIV.
Results
Design of packaging signal expression cassettes An HIV-1 particle is predicted to contain some 2000 to 2500 Gag proteins, but just two viral genomic RNA molecules. This stoichiometric imbalance, combined with the observation that efficient packaging can occur even when a small proportion of Gag-RNA interactions are productive, 20 suggests that a high concentration of packaging signal decoys would be necessary for effective interference. To this end, we used a multimerization strategy to increase the effective concentration of ⌿ elements. A 109 nucleotide portion of the viral genome containing the core packaging signal element was introduced into expression cassettes differing in the length and identity of their nonviral flanking sequences (Figure 1 ). These ⌿-containing fragments were multimerized by use of nonpalindromic restriction enzyme sites. Context-varied constructs were employed because RNA structure is critical to Gag recognition, 9 and some sequence contexts may obscure or destabilize the recognition of the packaging signal. 21 The ⌿ subunits were inserted singly or in tandem repeats into a mammalian expression plasmid selected for the reported high-level constitutive expression of its promoter (the human cytomegalovirus immediateearly promoter) in T lymphocytes. 22 Antisense controls were generated for single and multimeric forms, except for multimers of the smallest insert, for which antisense constructs could not be obtained.
Expression of packaging signal transcripts in T cells
Selected single or multimeric ⌿-expressing plasmids of each of the three context classes were stably transfected into Jurkat T lymphocytes by electroporation or lipofection and selection with G418. ⌿-Containing transcripts were detected by either RTPCR or RNase protection assays (RPA) of cytoplasmic RNA. Antisense riboprobes were generated directly from the expression plasmids; this strategy allowed discrimination of DNA and RNA. Representative RPAs of transcripts containing a single ⌿ copy of each of the three context types are shown in Figure 2a . In addition to a band corresponding to the fulllength transcript, a smaller protected fragment is also detectable when not obscured by the control ␤-actin protected fragment; this species probably reflects activity of the major splice donor contained within the ⌿ sequence. To address this inappropriate splicing, which removes the most important packaging determinant, a construct containing the viral RRE was also made. This RRE-containing construct, pP⌿1LGRRE, showed a higher proportion of unspliced transcript in the cytoplasm com- pared with the parental plasmid pH⌿1 (Figure 2b ). All lines were shown to contain the expected transcripts, with the exception of line pP⌿23a, which contains a plasmid expressing 23 copies of ⌿ in its shortest sequence context. RPA analysis of this transcript was inconclusive, due in part to the difficulty of obtaining an intact probe of this length; RTPCR detection of multimeric transcripts generated cross-hybridizing artifacts (data not shown).
Antiviral activity of packaging signal transcripts
Stable ⌿-expressing lines were challenged with HIV-1 IIIB, the strain from which the packaging signal sequences were derived. Lines were challenged in 96-well plates with between 1.06 × 10 1 and 2.25 × 10 4 TCID 50 per well of 5 × 10 4 cells, and replication was followed by RT activity. The 14 day post-infection time-point was predominantly used as a measure of viral inhibition, as this time-point generally represented the peak of RT activity and was a reliable measure of antiviral efficacy (data not shown). Up to 21 analyses were made of each cell line and a Kruskal-Wallis analysis of raw RT values was used to identify lines with statistically significant reductions in RT activity compared with the control line containing the backbone vector, pcDNA3. Figure 3a shows relative RT activities compared with the pcDNA3 control line for the six antiviral lines identified (out of 20 
cells. Numbers indicate positions of RNA markers (in nucleotides). (b) RPA analysis of the proportions of unspliced (closed arrow) to spliced (open arrow) transcripts generated from constructs with or without the Rev responsive element. Abbreviations as in (a).
non-control lines initially tested). Both single and multimeric decoy-expressing lines showed antiviral activity, and the effect persisted for up to 4 weeks ( Figure 3b ).
Mechanistic analysis of antiviral effect
The strong antiviral effects seen in selected lines led us to examine HIV-1 packaging efficiency in ⌿-expressing lines. If these transcripts were truly acting as encapsidation decoys, then the packaging efficiency (the amount of viral RNA present in the virion fraction as compared with its availability in the cytoplasm) should be reduced. Cytoplasmic and virion-associated RNA was extracted from large-scale challenges and subjected to RPA to detect viral RNA in three independent experiments. A representative result is shown in Figure 4a . Equal amounts of cytoplasmic RNA were analyzed, and, to correct for lower levels of virions in the supernatants of ⌿-expressing lines, virion RNA equivalent to a given value Gene Therapy of RT activity was used. The probe used 21 was able to distinguish viral RNA species (unspliced and spliced), viral DNA, and the ⌿ transcripts. However, there was no evidence in these experiments or others for packaging of the ⌿-containing transcripts (data not shown). Surprisingly, although the global amounts of viral RNA were lower, the encapsidation efficiency was not reduced in the antiviral lines. In fact, quantification of encapsidation ( Figure 4b ) revealed enhanced efficiencies compared with control Jurkats or Jurkats containing the backbone vector (pcDNA3) alone.
Figure 3 Viral challenge data for antiviral lines. (a) The RT activity of antirival lines 14 days after transfection expressed as a percent of the RT activity of the pcDNA3 line, which was challenged in parallel. Solid bars represent challenges at an input virus amount of 4.11

Specificity of antiviral effect
The finding that the ⌿ transcripts were not acting in their predicted manner as packaging signal decoys led us to examine the specificity of the antiviral effect by challenging with HIV-2 ROD. Lines pH⌿1a and pH␣⌿1, containing the sense and antisense orientations, respectively, of ⌿ in its shortest sequence context, were challenged as with HIV-1. Both lines showed inhibition of HIV-2 replication (Figure 5a ). To investigate the possibility that viral or plasmid sequences were fortuitously able to act as antisense or decoy molecules against HIV-2 RNA, a BestFit (GCG version 10.0) analysis was performed, but revealed no substantial sequence homology or potential for hybridization (Figure 5b) .
Reproducibility of antiviral effect
The ability of HIV-1 ⌿-expressing lines to inhibit both HIV-1 and HIV-2 may reflect inhibition of a cellular co- factor required by both viruses, or it may be a consequence of a general antilentiviral state induced in the selected Jurkat cells. To ascertain the reproducibility of the effect, replicate lines were generated from a subset of the plasmids that had been analyzed for antiviral activity. Plasmids associated with lines that had not inhibited virus replication when originally generated did not produce antiviral lines upon retransfection (Table 1) . Surprisingly, however, of the three plasmids tested again that had originally generated antiviral lines (pH⌿1, pP⌿23 and plB⌿1), none were able to reproduce this effect in replicate line preparations. A lack of consistency of plasmid effect was also suggested by the differing efficacy of pH⌿1 and pP⌿1 cell lines. Both plasmids are of the same subunit type (Figure 1) , differing by only one nucleotide in their flanking sequences, however, although the pH⌿1a line was antiviral, pP⌿1a was not (Table 1) .
This phenomenon could be related to a lower expression of transcripts in the ineffective lines. Lines generated from plasmid plB⌿1 were used to test this hypothesis. Quantitative RPA analysis was used to compare expression across replicate lines plB⌿1a, plB⌿1b and plB⌿1c ( Figure 6 ). Although plB⌿1a did show an antiviral effect, much less transcript was detectable in this line than in the high-expressing non-inhibitory line plB⌿1c.
The independence of antiviral effect upon ⌿ transcript expression level suggested that an unrelated cellular parameter was affecting antiviral efficacy. CD4 expression levels were measured by FACS analysis. A plot of relative CD4 expression level and antiviral efficacy (relative to the pcDNA3 line RT activity) revealed that only 25% of the variation in antiviral activity was linked to CD4 expression level variability (data not shown). Cellular proliferation rate of each of the lines was also examined, to determine if the observed antiviral effect might simply be a consequence of slower growth rates of particular lines. Proliferation was measured by a colorimetric metabolic assay, and relative proliferation rate was compared with relative antiviral effect. Spearman's rank correlation coefficient analysis revealed an r value of 0.39, suggesting no significant correlation between these two parameters (data not shown).
Discussion
The primary aim of this study was to examine the potential of transcripts containing the HIV-1 packaging signal 
lipofection # All lines were transfected by equivalent protocols (either electroporation or lipofection as noted) and selected with G418. Antiviral activity was determined by Kruskal-Wallis assessment of 14 days post-infection RT activity. to act as ⌿ decoys capable of interference with encapsidation. Of the 35 ⌿, ␣⌿ or RRE lines generated, six (17%) displayed statistically significant antiviral inhibition. None of three control lines (expressing plasmid backbone or GFP coding sequences) inhibited virus replication.
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The inhibition manifested as a profound delay in onset of detectable viral replication. The multiplicity of infection (MOI) (up to 0.45) used here is higher than most published studies, furthermore, the degree of inhibition compares favorably with those studies in which high MOI challenge has been investigated. 23, 24 A clue to the phenomenon observed came from ascertaining that the inhibition was not due to interference with packaging of viral RNA. In vitro binding experiments revealed that ⌿ transcripts were able to interact specifically with Gag in proportion to the number of ⌿ sequences present (data not shown), but in the intracellular environment, ⌿ transcript-mediated Gag binding was either not occurring, or of insufficient avidity or frequency to interfere functionally with encapsidation. Indeed, the ⌿ sequences were generally expressed at a very low level in the cell lines. We estimate that these transcripts are 40-to 100-fold less abundant than unspliced viral RNA in chronically infected Jurkats. This stoichiometric imbalance makes it unlikely that a substantive interference with Gag-genomic RNA binding could occur, particularly in HIV-1 infection where there is clear evidence of excess genomic RNA binding capacity, ie excess Gag, in infected cells. 25 Interestingly, two pcDNA3-based constructs containing the RRE, which in minimal form has been shown to exert a strong antiviral effect, 26, 27 displayed no evidence of inhibition of viral replication in this study (data not shown). Given that the RRE sequence was shown to be functional through detection of a higher proportion of intact ⌿-containing transcripts in the cytoplasm (Figure 2b) , the failure of the RRE decoys is likely due to low expression of these transcripts or the high input of virus used. Although an anti-HIV ribozyme has been documented to be effective at very low expression levels, 28 a decoy system lacks the catalytic capacity for multiple target turnover; this limitation probably causes a greater dependence on efficient expression.
Few studies of anti-HIV RNA decoys have included mechanistic information. In the majority of studies, either the mechanisms have not been investigated or investigations have been performed using transient transfection of subgenomic expression plasmids in non-physiological cell types. A follow-up study of a retroviral vector expressing a tRNA-TAR fusion transcript showed reduced levels of viral RNA in cells expressing the decoy. 29 However, this analysis was done 5 days after infection, so it remains possible that other early replication steps were also affected (although mutation analysis confirmed an intact loop structure was necessary for the efficacy of the TAR transcript). A similar analysis of the effects of a tRNA-RRE fusion transcript showed that although the proportion of full-length RNA transcripts was reduced in infected cells expressing the decoy, global levels of viral RNA were also reduced, suggesting another Rev-independent mechanism of inhibition. 26 Again, analyses were performed a number of days after infection, with the possibility of observing cumulative effects. Follow-up studies using these sequences in other vectors or contexts have not included any confirmation that the mechanism of inhibition remained at the level of Rev or Tat interference. Context effects appear to be influential in determining the efficacy of antiviral genes, 30 so an assumption of an identical mechanism may be illadvised in these circumstances. In studies of HIV-1 vec-Gene Therapy tors as packaging signal decoys, evidence of encapsidation of the vector is consistent with inhibition via packaging competition. 17, 19 By contrast, careful mechanistic analysis of non-mobilizable-containing antivirals is lacking, [10] [11] [12] [13] [14] [15] [16] and it remains unclear whether the antiviral effect observed in these studies is truly dependent on Gag sequestration.
The finding that HIV-2 replication was similarly inhibited by both sense and antisense constructs strongly suggested that the antiviral effects were not sequence specific. HIV-1 and HIV-2 are dissimilar viruses, sharing approximately 50% sequence homology. The respective packaging signals differ in location; HIV-1 ⌿ is predominantly downstream of the major splice donor, 31 while the dominant HIV-2 ⌿ sequence is mostly upstream of that splice site. 32 There are also functional differences in the packaging mechanisms of the two viruses. 33 HIV-2 has been reported to interfere with HIV-1, 34, 35 but the converse has not been described. Sequence-specific inhibition of a transcript coding for a cellular factor is also unlikely, as both sense and antisense orientations would not be predicted to be equally effective. It remains possible that a nonspecific effect mediated by RNA structure might result in inhibition of lentiviral replication. It has been suggested that a number of double-stranded RNA binding proteins, such as TBRP, 36, 37 Staufen, 38 and La 39 functionally interact with HIV-1 factors. Expression of a structured RNA might titrate these RNA binding proteins from their normal functions, thereby affecting viral replication. An mfold 40 RNA structure analysis of the ⌿ and ␣⌿ regions predicts that both are able to fold into structures containing high levels of secondary structure, motifs that persist within the context of the full-length pH⌿1 and pH␣⌿1 transcripts (data not shown). Expression of structured RNAs might also activate an interferon pathway. However, the double-stranded RNAinducible enzyme PKR is reported to require duplexes of at least 30 base pairs for activity, 41 and structural predictions show such extended duplexes are unlikely to form in these transcripts.
RNA-mediated effects are difficult to reconcile, however, with the observation that repeat transfections of antiviral plasmids did not create antiviral lines, although transcript expression was detectable. Indeed, quantification of transcript amounts revealed a higher expression level in an ineffective line compared with an antiviral line. Although an upper threshold of RNA amount exists for PKR activation, 41 an examination of cellular proliferation rate and antiviral effect failed to reveal a strong correlation between these factors. The interferon response is antiproliferative due to phosphorylation of the translation initiation factor eIF-2␣, 42 so the lack of evidence of slowed growth suggests the inhibition is primarily independent of an interferon pathway.
Examination of CD4 level and antiviral effect revealed a maximum correlation of 25% between these two factors. A correlation does not imply a causative effect, it could simply be the result of another factor affecting the variability of both measured parameters. Even if causative, this mild influence is insufficient to explain the results, particularly in light of a report that laboratory adapted HIV-1 strains (such as IIIB) are equally infectious for cells with trace or large amounts of CD4. 43 Many studies of RNA decoys have been limited to confirmation of expression, documentation of an antiviral effect, and analysis of cellular parameters such as CD4 expression level or proliferation rate. Had that been the extent of the work conducted within this study, and had our analysis been limited to a small number of antiviral cell lines, we would have erroneously concluded that the HIV-1 packaging signal sequence is a potent anti-HIV decoy. However, our mechanistic analysis found that the proposed inhibitory pathway was not followed. This finding led us to examine further the basis of the antiviral effect observed. We conclude that selection of cells containing heterologous expression vectors can result in the production of lines displaying profound resistance to lentiviral replication. It is possible that the RNA antiviral literature already contains instances of such effects, and researchers using similar systems should be aware of the potential to generate incidental cellular antiviral activity. Furthermore, these lines provide a resource with which to examine cellular factors influencing viral replication and may provide new sources of antiviral approaches to HIV therapy.
Materials and methods
Construction of packaging signal expression plasmids Each expression plasmid contains viral sequences corresponding to nucleotides (nt) 678 to 788 (numbering based on the pHXB2 proviral clone, 44 where 1 is the first nt of U3). Different constructs varied in the sequence context in which the amplified fragment was placed; the number of ⌿ inserts is indicated by the number contained in the name. In pH⌿1, this sequence was PCR-amplified with Pfu DNA polymerase using primers 5Ј-catgatccaa gctttggctctctcgacgcaggactcggcttg-3Ј and 5Ј-cttagaccaag ctttggctctctccttctagcctccgctagt-3Ј. The amplimer was digested with HindIII and ligated into HindIII-digested pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). For construction of pP⌿-based plasmids, 5Ј-catgatccaaagctt ggctctctcgacgc aggactcggcttg-3Ј was used as the 5Ј primer with the same 3Ј primer as before. The amplimer was digested with PflMI and ligated into pcDNA3 containing a C to A base substitution at position 892, causing the introduction of a PflMI recognition site. Plasmid pP⌿1LGRRE contains the PflMI-flanked ⌿ sequence followed by HIV-1 sequences starting 20 nt from the end of R and terminating 37 nt into gag, as well as a fragment of env bearing the RRE. It was generated by inserting a blunted HindIII (sites at positions 531 and 8138) fragment of LRPL 25 into a BamHI-blunt/EcoRV digest of pP⌿1. The discrete RRE was added by addition of viral sequences 7704 to 8063 to pP⌿1 prepared by BamHI-blunt/XhoI digestion. Control plasmids containing just the RRE sequences were also made. psB⌿ and plB⌿-based plasmids were generated using pcD⌬KB and pKS␣⌿ as starting materials. The KpnI, BamHI, and BstXI recognition sites were deleted from pcDNA3 to create pcD⌬KB, leaving a unique non-palindromic BstXI site. pKS␣⌿ consists of the ⌿ sequence inserted in reverse orientation into the HindIII site of pBluescript KSII (Stratagene, San Diego, CA, USA). For construction of psB⌿-based plasmids, an EcoRV/XbaI-blunt digest of pKS␣⌿ was religated to remove a stretch of sequence containing EcoRV, EcoRI, PstI, SmaI, BamHI, and SpeI recognition sites. This internally deleted plasmid was then digested with NotI/XhoI and ligated into a similarly digested pcD⌬KB. The resulting plasmid was cut at the ClaI site (derived from the pKS␣⌿ sequences) and blunted. An EcoRV/SmaI fragment from pcD⌬KB was then introduced at this site, generating a duplicate BstXI site 3Ј of the ⌿ sequences. This amplification plasmid contains ⌿ flanked by two BstXI sites. By digestion with BstXI, a fragment suitable for insertion or multimerization into the BstXI site of pcD⌬KB was created. For creation of plB⌿-based plasmids, an XhoI/XbaI digest of pKS⌿ (as pKS␣⌿ but in forward orientation) was ligated into the equivalent sites of pcD⌬KB. The resulting plasmid was linearized with ApaI and blunted for insertion of a EcoRV/SmaI fragment from pcD⌬KB. This created an amplification plasmid that could be digested with BstXI to create inserts able to multimerize in BstXI-digested pcD⌬KB. All plasmids were verified by sequencing or diagnostic restriction digests.
Stable transfection into Jurkat T cells
Jurkat cells were maintained in RPMI-1640 medium containing penicillin-streptomycin and 10% fetal bovine serum. Cells were transfected either by electroporation or lipofection. For electroporation, approximately 2 × 10 6
Jurkat cells per transfection were incubated with 10 g of plasmid DNA at 4°C and then electroporated at 550 mV and 25 F (Gene Pulser, Bio-Rad, Hercules, CA, USA). For lipofection, 10 g of DNA were transfected with Transfast Reagent (Promega, Madison, WI, USA) according to the manufacturer's instructions. In both cases, Jurkats were selected using 2 mg/ml G418 (Gibco BRL, Rockville, MD, USA; prepared in 100 mm Hepes, pH 7.3). Selected cells almost certainly represent polyclonal populations but are referred to as lines for simplicity.
RNase protection assay analysis of expression RNase protection assays were performed using reagents from or based upon a commercial kit (RPA II kit; Ambion, Austin, TX, USA) according to the manufacturer's instructions. RNA inputs into each reaction consisted of appropriate amounts of cytoplasmic or virion RNA, 1 × 10 5 to 2 × 10 5 c.p.m. of probe, and 1 to 3 g Torulla yeast RNA. Cellular RNA was prepared by cold lysis and nuclei pelleting, and virion RNA isolated by ultra-centrifugation through a sucrose cushion. 45 Equivalent amounts of cytoplasmic RNA were used (usually 10 g) and virion RNA was normalized to reverse transcriptase (RT) activity of the virion pellet (usually RNA corresponding to 5 × 10 4 c.p.m. of RT activity was used). Riboprobes for the detection of HIV-1 RNA were prepared from pKS⌿CS as previously described. 21 Riboprobes for detection of ⌿-containing transcripts were generated from each ⌿-expressing plasmid by linearization with SnaBI and in vitro transcription using SP6 RNA polymerase.
RT-PCR
RNA was purified by RNeasy (Qiagen, Hilden, Germany) purification columns. One microgram of RNA was treated with DNase essentially as described. 46 Reverse transcription reactions were performed using the Promega Reverse Transcription System according to the manufacturer's instructions. Primers used were 5Ј-aatacgactcactatagggagacc-3Ј and 5Ј-tgggagtggcaccttc-3Ј. Typically, 35 cycles were performed using 30 s steps with Gene Therapy denaturation, annealing, and extension temperatures of 94°C, 63°C and 72°C, respectively.
Viral challenge experiments
Standard challenge experiments were performed in 96-well plates. For each stably transfected Jurkat line to be tested, up to 18 wells were used. Each well contained 5 × 10 4 cells in 150 l RPMI. Each experiment contained the pcDNA3 line as a negative control for antiviral effect; most also included untransfected Jurkats as a second negative control and pH⌿1a as a positive control for antiviral effect. Wells were supplemented with 50 l of virus stock. In initial experiments, RT activity (based on a 10 l supernatant aliquot of each well) was measured every 3 to 7 days essentially as has been described. 47 Later experiments consisted of a single RT measurement at or around 14 days after infection. In both cases, medium was refreshed every 3 to 4 days.
Virus stocks were prepared using HIV-1 IIIB or HIV-2 ROD (NIBSC AIDS Reagent Programme, Potters Bar, UK) in Jurkat or Jurkat-Tat cells. TCID 50 determinations were made as described 48 using RT activity as indication of infection.
Ninety-five percent confidence limits were calculated as published. 49 Kruskal-Wallis calculations were done using a trial version of Arcus Quickstat (Biomedical version 1.2) available for download at http://www. camcode.com/arcus.htm.
FACS analysis of CD4 expression
Cells 2 × 10 5 of each line were stained with 5 l of a 1 in 100 dilution of antibody (mouse anti-CD4 conjugated either to R-phycoerythrin or fluorescein isothiocyanate (Caltag Laboratories, Burlingame, CA, USA)). Cells were analyzed on a FACSort flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). FACS data were analyzed using WinMDI (version 2.7; available for download at http://facs.scripps.edu/software.html).
Pearson's R test of linear correlation was performed using the web-based statistics server produced by the Institute of Phonetic Sciences at the University of Amsterdam (http://fonsg3.let.uva.nl:8001/Service/Statistics. html). F tests to check for equality of variance were calculated using a formula provided by Microsoft Excel (Office 97 version).
Proliferation analysis of cell lines
Assays to measure metabolic activity of cells were performed in parallel with challenge assays. Cells were dispensed to a flat-bottom 96-well plate. After 24 h, 20 l of Alamar-Blue redox indicator (Serotec, Oxford, UK) were added to each well to detect cellular metabolic reduction, and net absorbance readings were taken periodically for several hours thereafter on an ht2 microplate reader (Rosys Anthos, Hombrechtikon, Switzerland). Each line was scored for its relative proliferation compared with pcDNA3. Any line that displayed a higher proliferation than pcDNA3 was scored as '3', lower proliferation as '1', and proliferation insignificantly different than pcDNA3 as '2'. Significant difference was interpreted as plots in which the 95% confidence intervals did not overlap at more than one time-point. Following this scoring process, the non-parametric Spearman's rank correlation test (performed using the Institute of Phonetic Sciences web server) was used to determine the co-variation of proliferation and viral replication.
